Displaying drugs 1451 - 1475 of 2146 in total
NP-G2-044
NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).
Investigational
TRX-E-002-1
Investigational
HL001
Investigational
PBKR03
PBKR03 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, containing a transgene encoding the human galactosylceramidase (GALC) enzyme.
Investigational
CT041
CT041 is an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2).
Investigational
HG004
Investigational
Sasanlimab
Sasanlimab is under investigation in clinical trial NCT06218069 (Immuno-pet Imaging Responses Administered Immune Checkpoint Inhibitor).
Investigational
Covax-19™
Covax-19™, a protein-based vaccine, was developed through partnership between APC and Vaxine. It uses an insect-cell-produced recombinant SARS-CoV-2 spike protein and Vaxine’s adjuvant, Advax-SM. This adjuvant is designed to circumvent high fevers, fatigue, and aches experienced with other vaccines using more traditional adjuvants. Covax-19™ was tested in animal studies, and...
Investigational
Matched Description: … As of June 2020, the vaccine is in Phase 1 trials to evaluate safety and immune responses (NCT04428073 ... Phase 2 and 3 trials are planned for September 2020, and the vaccine is expected to launch early in 2021 …
DG031
DG031, deCODE genetics's lead compound, is being developed for the prevention of myocardial infarction, or heart attack.
Investigational
KB002
KB002 is an engineered human IgG1k antibody engineered human. It is developed for the treatment of autoimmune diseases, initially rheumatoid arthritis.
Investigational
PRX-07034
Investigational
GLPG-0259
GLPG-0259 is under investigation in clinical trial NCT01024517 (GLPG0259 Solid Formulation Bioavailability and Food Effect).
Investigational
PR006
PR006 is a non-replicating recombinant adeno-associated virus serotype 9 containing the progranulin gene. It is being investigated for the treatment of dementia.
Investigational
PBR-06 F-18
Investigational
NRC-AN-019
Investigational
SNS01-T
SNS01-T is a gene therapy nanoparticle. It is composed of three components: a B cell-specific plasmid expressing eIF5AK50R; an siRNA that targets the native eIF5A that promotes growth/anti-apoptosis of cancer cells; and polyethylenimine.
Investigational
RR001
RR001 is an investigational gene therapy consisting of autologous human adipose perivascular stromal cells genetically modified to secrete soluble tumour necrosis factor-related apoptosis-inducing ligand (AD-PC sTRAIL).
Investigational
TTAX01
TTAX01 is a cryopreserved human umbilical cord product being developed by TissueTech.
Investigational
ALMB-0166
ALMB-0166 is a umanized connexin 43 (Cx43) monoclonal antibody being investigated for the treatment of acute spinal cord injury. It was granted FDA orphan designation in November 2018.
Investigational
NX001
Investigational
EB003
EB003 is a CRISPR-based sequence-specific antimicrobial (SSAM) targeted against shiga toxin-producing E. coli.
Investigational
PBGM01
PBGM01 is a non-replicating recombinant adeno-associated virus serotype hu68 vector, which contains human GLB1 transgene encoding the galactosidase beta 1 enzyme.
Investigational
Displaying drugs 1451 - 1475 of 2146 in total